Cognition Therapeutics Inc (CGTX) concluded trading on Wednesday at a closing price of $0.62, with 18.53 million shares of worth about $11.49 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -16.69% during that period and on July 16, 2025 the price saw a gain of about 8.56%. Currently the company’s common shares owned by public are about 61.97M shares, out of which, 50.00M shares are available for trading.
Stock saw a price change of 15.84% in past 5 days and over the past one month there was a price change of 106.70%. Year-to-date (YTD), CGTX shares are showing a performance of -68.86% which decreased to -12.08% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.22 but also hit the highest price of $2.54 during that period. The average intraday trading volume for Cognition Therapeutics Inc shares is 6.60 million. The stock is currently trading 46.50% above its 20-day simple moving average (SMA20), while that difference is up 72.74% for SMA50 and it goes to 29.89% higher than SMA200.
Cognition Therapeutics Inc (NASDAQ: CGTX) currently have 61.97M outstanding shares and institutions hold larger chunk of about 9.13% of that.
The stock has a current market capitalization of $38.22M and its 3Y-monthly beta is at 0.86. It has posted earnings per share of -$0.73 in the same period. It has Quick Ratio of 2.09 while making debt-to-equity ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CGTX, volatility over the week remained 23.34% while standing at 16.34% over the month.
Analysts are in expectations that Cognition Therapeutics Inc (CGTX) stock would likely to be making an EPS of -0.1 in the current quarter, while forecast for next quarter EPS is -0.09 and it is -0.28 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.14 which is -0.06 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.18 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 52.62% while it is estimated to increase by 31.29% in next year. EPS is likely to grow at an annualized rate of 32.88% for next 5-years, compared to annual growth of -16.44% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by B. Riley Securities on December 19, 2024 offering a Buy rating for the stock and assigned a target price range of between $1 and $1.50 to it. On November 03, 2021, Oppenheimer Initiated their recommendations, while on November 03, 2021, B. Riley Securities Initiated their ratings for the stock with a price target of $27.
